Shares of Mirna Therapeutics Inc. (NASDAQ:MIRN) reached a new 52-week low during mid-day trading on Monday . The company traded as low as $2.95 and last traded at $2.95, with a volume of 181,962 shares trading hands. The stock had previously closed at $3.06.

MIRN has been the topic of a number of research reports. Zacks Investment Research upgraded Mirna Therapeutics from a “hold” rating to a “buy” rating and set a $5.00 price objective on the stock in a research report on Thursday, July 14th. Cantor Fitzgerald reiterated a “buy” rating and issued a $14.00 price target on shares of Mirna Therapeutics in a research report on Friday, May 13th. Leerink Swann cut Mirna Therapeutics from an “outperform” rating to a “market perform” rating and lowered their price target for the company from $10.00 to $4.00 in a research report on Monday, August 15th. Citigroup Inc. cut Mirna Therapeutics from a “buy” rating to a “neutral” rating and lowered their price target for the company from $7.00 to $4.50 in a research report on Tuesday, August 16th. Finally, Oppenheimer Holdings Inc. upped their price target on Mirna Therapeutics from $7.00 to $13.00 and gave the company an “outperform” rating in a research report on Tuesday, August 16th. Three equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. The stock has a consensus rating of “Hold” and an average target price of $8.10.

The firm’s market cap is $50.00 million. The company has a 50 day moving average of $3.93 and a 200 day moving average of $4.28.

Mirna Therapeutics, Inc is a United States-based clinical-stage biopharmaceutical company. The Company is focused on developing a pipeline of microRNA (ribonucleic acid)-based oncology therapeutics. It is developing a cancer therapy, microRNA Replacement Therapy, focused on replacing naturally occurring microRNAs that are under expressed in cancer cells with microRNA mimics.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.